Gefitinib topical composition containing water-soluble polymer

By combining polyethylene caprolactam graft copolymer with gefitinib, the problem of precipitation and absorption of gefitinib in the gastrointestinal tract is solved, achieving higher bioavailability and release, ensuring the stability of the drug and clinical effects.

CN119015289APending Publication Date: 2024-11-26CHINA PHARM UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310589811.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-24
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Due to its pH-dependent solubility characteristics, gefitinib is difficult to absorb in the stomach, resulting in low bioavailability and easy precipitation in the small intestine. The existing water-soluble cellulose materials have limited effects in inhibiting precipitation and are difficult to last for a long time. Maintain the drug in a high supersaturation state.

Method used

Polyethylene caprolactam graft copolymer is used as an amphiphilic nonionic pharmaceutical polymer material, combined with gefitinib, and dispersed uniformly by grinding to form a pharmaceutical composition to reduce the precipitation rate and improve the release degree.

Benefits of technology

It effectively delays the precipitation rate of gefitinib, improves its bioavailability in the human gastrointestinal tract, and ensures good clinical effect. The polyethylene caprolactam graft copolymer significantly inhibits the precipitation of drugs within a specific dosage range. And maintain a high release level.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119015289A_ABST
    Figure CN119015289A_ABST
Patent Text Reader

Abstract

The invention provides a gefitinib local composition containing a water-soluble polymer. The gefitinib pharmaceutical composition comprises an active component gefitinib or a pharmaceutically acceptable salt thereof or a solvate thereof and an amphipathic nonionic medicinal polymer material. The content of the active component accounts for 30%-96% of the total weight of the composition, the content of the amphiphilic nonionic medicinal high polymer material accounts for 0.01%-70% of the total weight of the composition, and the amphiphilic nonionic medicinal high polymer material is a polyethylene caprolactam-polyvinyl acetate-polyethylene glycol grafted copolymer. The polyethylene glycol copolymer substance in the gefitinib pharmaceutical composition can reduce the precipitation of gefitinib, so that the precipitation rate of gefitinib can be delayed, the bioavailability of gefitinib in the gastrointestinal tract of a human body is improved, and a good clinical effect is ensured.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of medicine, and in particular relates to a gefitinib local composition containing a water-soluble polymer. Background Art

[0002] Gefitinib is a type of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that can block the EGFR signaling pathway, ultimately producing a series of biological effects such as inhibiting tumor cell proliferation and metastasis and promoting tumor cell apoptosis. Gefitinib was developed by AstraZeneca. In August 2002, Japan first approved gefitinib tablets (Iressa) as a drug for the treatment of non-small cell lung cancer. In February 2005, the State Food and Drug Administration approved gefitinib tablets for the treatment of locally advanced or metastatic non-small cell lung cancer that had previously received chemotherapy. In November 2010, it was approved for the first-line treatment of locally advanced or metastatic non-small cell lung cancer with sensitive mutations in the epidermal growth factor receptor tyrosine kinase (EGFR-TK) gene.

[0003] Gefitinib belongs to BCS II weak alkaline drugs. Its solubility in aqueous solution is pH-dependent. The lower the pH of the aqueous solution, the greater its solubility. Its solubility drops sharply between pH 4 and 6, and it is almost insoluble in aqueous solution above pH 7. Since the solubility is pH-dependent, the drug first dissolves in the stomach, but the drug stays in the stomach for a relatively short time and is difficult to be fully absorbed by the stomach. Literature reports that its bioavailability in the stomach is only 59%. When entering the small intestine, the intestinal pH value increases, so gefitinib is easily precipitated from the solution, making it difficult for the drug to be absorbed in the intestine, thereby affecting the absorption and bioavailability of the drug.

[0004] Since the drug spontaneously reaches a supersaturated state during the transfer from the stomach to the small intestine, precipitation inhibitors (PIs) can be used to maintain the supersaturated state of the drug in the small intestine, thereby prolonging the time for the drug to be absorbed. Water-soluble polymer materials are an important component of drug dosage forms and can be used as fillers, coating liquids, skeleton materials, etc. in preparations. They have a significant inhibitory effect on the precipitation of weakly alkaline drugs and can significantly increase the bioavailability of drugs.

[0005] Patent CN03804616.4 discloses a pharmaceutical composition comprising a pharmaceutically active ingredient or a pharmaceutically acceptable salt thereof (reagent) and a water-soluble cellulose ether or an ester of a water-soluble cellulose ether, wherein the pharmaceutically active ingredient is gefitinib or a pharmaceutically acceptable salt thereof or a solvate thereof, and the water-soluble cellulose ether or the ester of a water-soluble cellulose ether present in the composition inhibits the rate at which the reagent precipitates from the solution. In this patent, low-viscosity HPMC is used as a film coating material, and the dosage is limited, and 8.16 mg of HPMC has a very limited effect in inhibiting drug precipitation.

[0006] Patent CN 103845335 A discloses a composition containing a pharmaceutically active ingredient and a hydrophilic copolymer, wherein the pharmaceutically active ingredient is gefitinib or a pharmaceutically acceptable salt thereof or a solvate thereof, and the polyacrylic acid resin substance present in the composition inhibits the rate at which the reagent precipitates from the solution. In this patent, polyacrylic acid resin substances are added to the core of the gefitinib pharmaceutical composition, which alleviates the problem of gefitinib precipitation under neutral conditions to a certain extent, but this degree of precipitation inhibition cannot improve the bioavailability of gefitinib in clinical use, and the product batch-to-batch uniformity is poor, which is not conducive to slowing down the precipitation of gefitinib.

[0007] Patent CN 108096251 A discloses a composition containing a pharmaceutically active ingredient and a hydrophilic copolymer, wherein the pharmaceutically active ingredient is gefitinib or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein the copolyvidone can inhibit the sedimentation of the active ingredient in the pharmaceutical composition due to changes in pH in the body and improve the in vivo bioavailability of the pharmaceutically active agent.

[0008] Most of the existing water-soluble cellulose materials are used as film coating materials, and their usage is limited, so the inhibitory effect on drug precipitation is not obvious. In patent CN03804616.4, the effect of HPMC in inhibiting drug precipitation is very limited.

[0009] In patent CN 103845335 A, polyvinyl acid resin is used as the core material. When the dosage is about 10 mg, after the pH is increased, the drug content still drops to less than 10% within 45 minutes. In patent application CN 108096251 A, PVPVA is used as the core material. When the dosage is small, its inhibitory effect is not obvious. When the dosage is large, the tablet weight increases too much and poor dissolution is prone to occur. The above technology can only slow down the precipitation of gefitinib to a certain extent, and cannot maintain the drug in a highly supersaturated state for a long time. Moreover, the inhibitory effect of the above materials on the precipitation of the drug is related to its dosage. When the dosage is small, the inhibitory effect is not obvious. When the dosage is large, the tablet weight increases too much and poor dissolution is prone to occur.

[0010] Therefore, it is a challenge for researchers to provide a new gefitinib pharmaceutical composition to reduce the rate at which gefitinib precipitates from the solution and increase the retention time of the drug. Summary of the invention

[0011] In view of the above technical problems existing in the prior art, the present invention provides a gefitinib pharmaceutical composition which improves the release of gefitinib and inhibits the precipitation of gefitinib.

[0012] A gefitinib pharmaceutical composition comprises an active ingredient gefitinib or a pharmaceutically acceptable salt thereof or a solvate thereof and an amphiphilic nonionic pharmaceutical polymer material.

[0013] Furthermore, the active ingredient content is 30%-97% of the total weight of the composition; preferably, the active ingredient content is 72-96.2% of the total weight of the composition; further preferably, the active ingredient content is 72-84% of the total weight of the composition.

[0014] Furthermore, the amphiphilic nonionic pharmaceutical polymer material is 0.01% to 70% of the total weight of the composition; preferably, the amphiphilic nonionic pharmaceutical polymer material is 3.8% to 28% of the total weight of the composition; further preferably, the amphiphilic nonionic pharmaceutical polymer material is 16% to 28% of the total weight of the composition.

[0015] Furthermore, the amphiphilic nonionic pharmaceutical polymer material is selected from at least one of polyvinyl caprolactam graft copolymers, polyvinyl ether copolymers, and polyvinyl alcohol copolymers.

[0016] Furthermore, the amphiphilic nonionic pharmaceutical polymer material is a polyvinyl caprolactam graft copolymer.

[0017] Furthermore, the amphiphilic nonionic pharmaceutical polymer material is a polyethylene caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer.

[0018] The preparation method of the above-mentioned pharmaceutical composition comprises: grinding and dispersing gefitinib or a pharmaceutically acceptable salt or a solvate thereof, mixing with a polyethylene glycol graft copolymer, and fully dispersing the mixture evenly.

[0019] The technical solution of the present invention has the following beneficial effects compared with the prior art:

[0020] The polyvinyl caprolactam graft copolymer in the gefitinib pharmaceutical composition of the present invention can reduce the precipitation of gefitinib, which will help to delay the precipitation rate of gefitinib, improve the bioavailability of gefitinib in the human gastrointestinal tract, and ensure good clinical effects.

[0021] The precipitation rate of gefitinib in the solution is described by the precipitation rate constant (PRC), and the calculation process is shown in formula (1), where Pt is the amount of drug precipitated in the intestine, and Ct is the amount of drug dissolved at time t. When the precipitation rate constant is larger, the precipitation speed of gefitinib is faster; when the precipitation rate constant is smaller, the precipitation speed is slower, and the precipitation inhibition effect of the polymer and copolymer is stronger.

[0022] Pt=Ct×PRC Formula (1) BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 Release profiles of Examples AE in a two-stage dissolution method;

[0024] Figure 2 Release curves of control examples ad in the two-stage dissolution method;

[0025] Figure 3 Release profile of control example he in the two-stage dissolution method.

[0026] Figure 4 Release curves of Examples B and E and Comparative Examples b and f for inhibiting precipitation in a two-stage dissolution method. DETAILED DESCRIPTION

[0027] The present invention is further explained below with reference to the examples, but the examples do not limit the present invention in any form.

[0028] Example 1

[0029] The prescribed amount of gefitinib was weighed into a mortar and then ground evenly with a pestle, and then a polyvinyl caprolactam graft copolymer (polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, Soluplus) in the proportion shown in Table 1 was added and mixed until a uniform mixture was obtained.

[0030] Table 1 Mass ratio of gefitinib and Soluplus

[0031]

[0032] The dissolution rate and precipitation rate of the gefitinib composition in the two-stage dissolution method in Example 1 were investigated. The dissolution test described in the present invention was carried out under the conditions of the physiologically relevant dissolution medium FassGF and FassIF-V2, that is, the dissolution test was carried out in a paddle method with a rotation speed of 100 rpm. The pharmaceutical composition described in the present invention was added to 250 mL of FaSSGF (a medium simulating fasting gastric fluid) solution, and the FaSSGF solution containing the drug was transferred to 350 mL of FaSSIF (a medium simulating fasting intestinal fluid) solution within 30 minutes using a peristaltic pump.

[0033] The dissolution test data of Example 1 are shown in Table 2, and the dissolution curve is shown in Figure 1 , where the horizontal axis is time (min), the vertical axis is the release of the active ingredient gefitinib (%), the precipitation rate results are shown in Table 3 (30min to 180min), and the dissolution curve results show that the experimental examples AD in Example 1 can increase the release of gefitinib in the simulated physiological medium, and the release is maintained at more than 60% at 2h, which will help to delay the precipitation rate of gefitinib, improve the bioavailability of gefitinib in the human gastrointestinal tract, and ensure good clinical effects. While the release of Example E without the addition of polyvinyl caprolactam graft copolymer is rapidly reduced in the two-stage dissolution experiment, the drug is rapidly precipitated, and the release is only 51% at 2h. The precipitation rate results show that the experimental examples AD in the embodiment can reduce the precipitation of gefitinib in the simulated physiological medium, and when a small amount of polyvinyl caprolactam graft copolymer is added, there is a significant precipitation inhibition effect.

[0034] Table 2 Release of Example 1 in the two-stage dissolution experiment (%)

[0035]

[0036]

[0037] Table 3 Sedimentation rate constant results of Example 1

[0038]

[0039] Comparative Example 1: Referring to the embodiment of patent CN03804616.4

[0040] The prescribed amount of gefitinib was weighed into a mortar, then ground evenly with a pestle, and then HPMC in the proportion in Table 4 was added and mixed until a uniform mixture was obtained.

[0041] Table 4 Mass ratio of gefitinib to HPMC

[0042]

[0043] The release and precipitation rate of the gefitinib composition in the two-stage dissolution experiment in Comparative Example 1 were investigated. The dissolution experiment described in the present invention was carried out under the conditions of the physiologically relevant dissolution medium FassGF and FassIF-V2, that is, the dissolution test was carried out in a paddle method with a rotation speed of 100 rpm. The pharmaceutical composition described in the present invention was added to 250 mL of FaSSGF (a medium simulating fasting gastric fluid) solution, and the FaSSGF solution containing the drug was transferred to 350 mL of FaSSIF (a medium simulating fasting intestinal fluid) solution within 30 minutes using a peristaltic pump.

[0044] The release rate of Experimental Example ad in Comparative Example 1 is shown in Table 5, and the dissolution curve is shown in Figure 2 , where the abscissa is time (min) and the ordinate is the release rate of gefitinib (%). The precipitation rate results are shown in Table 6 (30min to 180min). The dissolution curve results show that the experimental examples ad in Comparative Example 1 can increase the release of gefitinib in the simulated physiological medium to a certain extent. The results show that HPMC can play a certain precipitation inhibitory effect on the active ingredient gefitinib in the two-stage dissolution method, but at 30min, the gefitinib release in the comparative example 1 is up to 80.66%, and at 2h, the gefitinib release in the comparative example 1 is up to 53.61%, which is not as obvious as the inhibitory effect of the polyvinyl caprolactam graft copolymer in Example 1. The precipitation rate results show that the experimental examples ad in the comparative example can reduce the precipitation of gefitinib in the simulated physiological medium to a certain extent.

[0045] Table 5 Release of Control Example 1 in the Two-stage Dissolution Experiment (%)

[0046]

[0047] Table 6 Precipitation rate constant results of Comparative Example 1

[0048]

[0049] Comparative Example 2:

[0050] The prescribed amount of gefitinib was weighed into a mortar and then ground evenly with a pestle, and then PVP in the proportion in Table 7 was added and mixed until a uniform mixture was obtained.

[0051] Table 7 Mass ratio of gefitinib and PVP

[0052]

[0053] The release and precipitation rate of the gefitinib composition in the two-stage dissolution experiment in Comparative Example 2 were investigated. The dissolution experiment described in the present invention was carried out under the conditions of the physiologically relevant dissolution medium FassGF and FassIF-V2, that is, the dissolution test was carried out in a paddle method with a rotation speed of 100 rpm. The pharmaceutical composition described in the present invention was added to 250 mL of FaSSGF (a medium simulating fasting gastric fluid) solution, and the FaSSGF solution containing the drug was transferred to 350 mL of FaSSIF (a medium simulating fasting intestinal fluid) solution within 30 minutes using a peristaltic pump.

[0054] The release rate of experimental example eh in comparative example 2 is shown in Table 8, and the dissolution curve is shown in Figure 3, where the abscissa is time (min) and the ordinate is the release rate of gefitinib (%). The precipitation rate results are shown in Table 9 (30min to 180min). The dissolution curve results show that the experimental example eh in Comparative Example 2 can increase the release of gefitinib in the simulated physiological medium to a certain extent. At 30min, the gefitinib release in the control example 2 is up to 76.89%, and at 2h, the gefitinib release in the control example 1 is up to 53.95%, which is not as obvious as the inhibitory effect of the polyvinyl caprolactam graft copolymer in Example 1 and the cellulose polymer in Comparative Example 1. The precipitation rate results show that the comparative example eh in the comparative example can reduce the precipitation of gefitinib in the simulated physiological medium to a certain extent.

[0055] Figure 4 The results show that in the composition of the same mass ratio, different polymers have an effect on the release and precipitation rate of gefitinib. The results show that the polyvinyl caprolactam graft copolymer in Example 1 can not only inhibit the precipitation of the drug, but also improve the release of the drug. Although the cellulose polymer in Comparative Example 1 and the PVP in Comparative Example 2 also have the effect of inhibiting precipitation to a certain extent, due to their lower release, the overall precipitation inhibition effect is not as good as that of the polyvinyl caprolactam graft copolymer in Example 1.

[0056] Table 8 Release of Comparative Example 2 in the two-stage dissolution experiment (%)

[0057]

[0058] Table 9 Precipitation rate constant results of Comparative Example 2

[0059]

[0060] In summary, the gefitinib pharmaceutical composition of the present invention adopts the polyvinyl caprolactam graft copolymer Solplus, which can reduce the precipitation of gefitinib within at least 180 minutes within the special dosage range of the present invention, and at the same time improve the release of gefitinib. The gefitinib pharmaceutical composition of the present invention helps to delay the precipitation rate of gefitinib, improve the bioavailability of gefitinib in the human gastrointestinal tract, and ensure good clinical effects.

[0061] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A gefitinib pharmaceutical composition, It is characterized in that The gefitinib pharmaceutical composition comprises an active ingredient, gefitinib or a pharmaceutically acceptable salt thereof or a solvate thereof and an amphiphilic nonionic pharmaceutical polymer material.

2. The gefitinib pharmaceutical composition according to claim 1, It is characterized in that The active ingredient content is 30%-97% of the total weight of the composition; preferably, the active ingredient content is 72-96.2% of the total weight of the composition; further preferably, the active ingredient content is 72-84% of the total weight of the composition.

3. The gefitinib pharmaceutical composition according to claim 1, It is characterized in that The amphiphilic nonionic pharmaceutical polymer material accounts for 0.01% to 70% of the total weight of the composition; preferably, the amphiphilic nonionic pharmaceutical polymer material accounts for 3.8% to 28% of the total weight of the composition; further preferably, the amphiphilic nonionic pharmaceutical polymer material accounts for 16% to 28% of the total weight of the composition.

4. The gefitinib pharmaceutical composition according to claim 1, It is characterized in that The amphiphilic nonionic pharmaceutical polymer material is selected from at least one of polyvinyl caprolactam graft copolymers, polyvinyl ether copolymers and polyvinyl alcohol copolymers.

5. The gefitinib pharmaceutical composition according to claim 1, It is characterized in that The amphiphilic nonionic medicinal polymer material is a polyvinyl caprolactam graft copolymer.

6. The gefitinib pharmaceutical composition according to claim 1, It is characterized in that The amphiphilic nonionic medicinal polymer material is a polyethylene caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer.

7. A method for preparing the pharmaceutical composition according to any one of claims 1 to 6, It is characterized in that The preparation method comprises: grinding and dispersing gefitinib or a pharmaceutical salt or a solvate thereof, mixing with a polyethylene glycol graft copolymer, and fully dispersing the mixture.